Skye Bioscience (SKYE) CEO receives 1.09M RSU award vesting 2027

Rhea-AI Filing Summary

DHILLON PUNIT reported acquisition or exercise transactions in this Form 4 filing.

Skye Bioscience CEO Punit Dhillon received a grant of 1,090,000 restricted stock units tied to common stock on August 7, 2026. Each RSU represents one share and will vest on August 31, 2027, subject to continued employment or certain termination conditions under his Executive Employment Agreement. Following this award, he reports 1,419,823 shares held directly plus 9,343 shares held indirectly through a trust.

Insider Trade Summary

Net Buyer: 1,090,000 shares

Net Buy 2 txns

Insider DHILLON PUNIT

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	1,090,000	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,419,823 shares (Direct); Common Stock — 9,343 shares (Indirect, Trust)

Footnotes (2)

1. F1. Represents a restricted stock unit ("RSU") award that will vest on August 31, 2027 subject to (a) the Reporting Person's continued employment through such date or (b) the termination of the Reporting Person's employment by the Company for any reason other than For Cause, By Death or By Disability (each, as defined in the Reporting Person's Executive Employment Agreement), provided the Reporting Person executes and does not revoke the release agreement appended to the Reporting Person's Executive Employment Agreement.
2. F2. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Key Figures

RSU award size: 1090000 shares Direct holdings after grant: 1419823 shares Indirect holdings via trust: 9343 shares +2 more

5 metrics

RSU award size 1090000 shares Restricted stock units granted to CEO Punit Dhillon on August 7, 2026

Direct holdings after grant 1419823 shares Common stock reported as held directly by the CEO following the RSU award

Indirect holdings via trust 9343 shares Common stock reported as held indirectly through a trust

RSU vesting date August 31, 2027 Vesting date for the 1,090,000 restricted stock units, subject to employment conditions

Grant price per share 0.0000 per share Compensation grant; no cash price paid for the RSU award

Key Terms

restricted stock unit ("RSU"), Executive Employment Agreement, Trust

3 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") award that will vest on August 31, 2027"

Executive Employment Agreement regulatory

"each, as defined in the Reporting Person's Executive Employment Agreement"

Trust financial

"Indirect ownership type reported as Trust for 9,343 common shares"

A trust is a legal setup in which one party (the trustee) holds and manages assets—like cash, stocks or property—on behalf of other people (beneficiaries) according to instructions from the person who created it (the grantor). Think of it as a locked box with a keyholder who must follow written rules; for investors it matters because trusts influence who controls and benefits from assets, affect taxes and succession, and can change how quickly or transparently shares are bought, sold or voted.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/07/2026 - 05:38 PM Accepted by SEC EDGAR 08/07/2026 - 05:37 PM Learn about SEC filing dates

FAQ

What stock award did Skye Bioscience (SKYE) CEO Punit Dhillon receive?

Punit Dhillon received a grant of 1,090,000 restricted stock units tied to common stock on August 7, 2026. Each RSU equals one share and is treated as a compensation award rather than a market purchase at a cash price.

When do Punit Dhillon’s new RSUs in SKYE vest and what are the conditions?

The 1,090,000 RSUs vest on August 31, 2027. Vesting requires his continued employment through that date, or certain qualifying terminations by the company, plus execution and non-revocation of a release under his Executive Employment Agreement.

How many Skye Bioscience (SKYE) shares does Punit Dhillon hold after this Form 4?

After the reported award, Punit Dhillon reports 1,419,823 shares held directly and an additional 9,343 shares held indirectly through a trust, according to the ownership totals shown in the filing’s non-derivative holdings table.

What does each RSU granted to the Skye Bioscience (SKYE) CEO represent?

Each restricted stock unit granted to the CEO represents a contingent right to receive one share of Skye Bioscience common stock. The units convert into shares only upon satisfying the stated vesting and employment-related conditions.

Are Punit Dhillon’s SKYE transactions reported under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as an affirmed plan, and no footnote states that the RSU grant was made under a Rule 10b5-1 trading arrangement; it appears as a standard equity compensation grant.

How are Punit Dhillon’s indirect Skye Bioscience (SKYE) holdings structured?

The Form 4 shows 9,343 shares held indirectly with the ownership nature listed as “Trust.” This indicates a trust structure holds those shares, separate from his directly owned common stock position.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DHILLON PUNIT

(Last) (First) (Middle)

11250 EL CAMINO REAL, SUITE 100

C/O SKYE BIOSCIENCE, INC.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Skye Bioscience, Inc. [ SKYE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/07/2026		A		1,090,000(1)	A	$0(2)	1,419,823	D
Common Stock								9,343	I	Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award that will vest on August 31, 2027 subject to (a) the Reporting Person's continued employment through such date or (b) the termination of the Reporting Person's employment by the Company for any reason other than For Cause, By Death or By Disability (each, as defined in the Reporting Person's Executive Employment Agreement), provided the Reporting Person executes and does not revoke the release agreement appended to the Reporting Person's Executive Employment Agreement.

2. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Remarks:

	Punit Dhillon	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)